Imperial Brands Full-Year Net Revenue Growth Misses Views Slightly
By Elena Vardon
Imperial Brands posted net revenue growth slightly below expectations for fiscal 2023 but a better adjusted operating profit growth for the year as it continues to offset volume declines with strong pricing.
The FTSE 100 tobacco group--which houses Davidoff, Gauloises and JPS among its brands--said net revenue from tobacco and its next-generation products--which include vape, heated tobacco and oral nicotine products--was 8.01 billion pounds ($9.84 billion), or 0.7% on-year growth at constant currency. The group had guided for low-single-digit organic growth while analysts polled in a company-compiled consensus had expected the figure to improve 1%, and to report GBP8.04 billion, from the previous year's GBP7.79 billion result.
The cigarette maker reported an adjusted operating profit--one of its preferred metrics--of GBP3.89 billion for the year ended Sept. 30, behind analyst expectations of GBP3.91 billion, which represents 3.8% on-year growth. It guided for growth at the lower end the of mid-single-digit range while consensus had seen 3.5% organic growth against the GBP3.69 billion reported for the year-prior period.
The board declared a dividend 146.82 pence per share, compared with the previous year's 141.17 pence payout while analysts had expected a 145.1 pence per share return.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
November 14, 2023 02:43 ET (07:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth